David L. Barker, PhD
Chairman

David L. Barker currently serves on the board of directors at Bionano Genomics and AmideBio and is a board member and chairman at Integrated Diagnostics and IntegenX, Inc.

Read More

Dr. Barker is a scientific advisor to MiNDERA Corp. and Illumina, Inc., where he was vice president and chief scientific officer from 2000 to 2007. He was previously on the boards of NextBio, which was acquired by Illumina in 2013; ProteinSimple, which was acquired by Bio-Techne in 2014; and Zephyrus Biosciences, Inc., which was acquired by Bio-Techne in 2016. Dr. Barker served, from 1998 to 2000, as vice president and chief science advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including vice president of research and business development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.

In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School and was an assistant professor at the University of Oregon and an associate professor at Oregon State University. Dr. Barker holds a bachelor’s degree, with honors, in chemistry from the California Institute of Technology and a PhD in biochemistry from Brandeis University.

Read Less
Erik Holmlin, PhD
President and Chief Executive Officer

Erik Holmlin is a dynamic leader with more than two decades of experience developing innovative solutions and companies in the life sciences and healthcare industries.

Read More

Erik’s experience includes positions at GenVault Corporation (CEO), Exiqon A/S (CCO) and Becton Dickinson (vice president of marketing and development). In 2001, Erik led the formation and financing efforts of GeneOhm Sciences, Inc. and orchestrated the company’s acquisition by Becton Dickinson in 2006. He also served as an entrepreneur in residence (EIR) at leading life-science venture capital firm Domain Associates, LLC.

Erik was a National Institutes of Health postdoctoral fellow at Harvard University and a National Science Foundation predoctoral fellow at the California Institute of Technology, Pasadena (Caltech). He holds a PhD in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.

Read Less
Darren Cai, PhD
Director

Dr. Daqing Cai, also known as Darren, joined Legend Capital in May 2011 as a director and is now an executive director.

Read More

Dr. Cai focuses on investment opportunities in the health care sector and has led LC’s investments in various companies, including Berry Genomics, Ustar, Shenogen, Cardea, BioHermes, Bionano, Hemay and Paige. Prior to joining Legend Capital, Dr. Cai worked with SBI-SDJB, a joint venture of SBI Group and Beida Jade Bird Group, as a managing director. He has also worked with Sinochem (Hong Kong) and Booz & Co. in senior management positions. He was a board member and CFO of Beijing Genomics Institute. Dr. Cai holds a PhD from University of California, Berkeley; an MBA from Yale University; and a bachelor’s degree from University of Science and Technology of China.

Read Less
Brian K. Halak, PhD
Director

Brian Halak joined Domain Associates, LLC in 2001 and became a partner in 2006.

Read More

Dr. Halak currently serves on the board of several life sciences companies, including Alimera Sciences, Dicerna Pharmaceuticals and Kona Medical. He was previously on the board of Esprit Pharma, until the company was acquired by Allergan and Vanda Pharmaceuticals.

From 2000 to 2001, Dr. Halak was an associate with Advanced Technology Ventures, where he participated in the firm’s investments in Plexxikon, Percardia and Emphasys. From 1993 to 1995, he was a consultant at the Wilkerson Group, where he developed strategy for pharmaceutical and medical device companies. Dr. Halak holds a bachelor’s degree in engineering from the University of Pennsylvania and a PhD from Thomas Jefferson University.

Read Less
Albert Luderer, PhD
Independent Director

Albert Luderer has three decades of experience in biotechnology, with special focuses on technology, business development and commercialization.

Read More

Dr. Luderer is CEO and board director at personalized diagnostics company Integrated Diagnostics. He also serves as CEO and board director of molecular therapeutics and imaging company Indi Molecular.

Dr. Luderer previously served as president and CEO of BioTrove, a venture-backed molecular biological tools company that was acquired by Life Technologies. Additionally, Dr. Luderer was CEO of venture-backed therapeutics company Light Sciences and president and COO of bioMérieux, Inc.

Senior management positions at Dianon Systems (LabCorp), Boehringer Mannheim (Roche), and Corning round out Dr. Luderer’s experience in the industry. He earned his PhD from Rutgers University, where he was a National Science Foundation predoctoral fellow, and performed postgraduate work in immunology at Jefferson Medical College.

Read Less
X

Discover what’s missing in your research

Let's talk